EUVIMEDEUVIMED entdecken
Historischer BeitragOpen Access

The Mortality-to-Incidence Ratio Is Not a Valid Proxy for Cancer Survival

Libby Ellis, Aurélien Belot, Bernard Rachet, Michel P Coleman

Journal of Global Oncology · 2019-12 · (5) · 1-9

DOI: 10.1200/jgo.19.00038 ↗

Kurz gefasst

Historischer Beitrag in der Zeitschrift Journal of Global Oncology, 2019-12. Verfasst von Libby Ellis und 3 weiteren Autor:innen. Beteiligte Einrichtung: London School of Hygiene and Tropical Medicine, London, United Kingdom. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The ratio of cancer mortality and cancer incidence rates in a population has conventionally been used as an indicator of the completeness of cancer registration. More recently, the complement of the mortality-to-incidence ratio (1-M/I) has increasingly been presented as a surrogate for cancer survival. We discuss why this is mistaken in principle and misleading in practice. METHODS We provide an empirical assessment of the extent to which trends in the 1-M/I ratio reflect trends in cancer survival. We used national cancer incidence, mortality and survival data in England to compare trends in both the 1-M/I ratio and net survival at 1, 5, and 10 years for 19 cancers in men and 20 cancers in women over the 29-year period from 1981 to 2009. RESULTS The absolute difference between the 1-M/I ratio and 5-year net survival for 2009 was less than 5% for only 12 of the 39 cancer/sex combinations examined. For an additional 12, the 1-M/I ratio differed from 5-year net survival by at least 15%. The comparison is also unstable over time; thus, even when differences were small for 2009, the difference between 5-year net survival and the 1-M/I ratio had changed dramatically for most cancers between 1981 and 2009. CONCLUSION The 1-M/I ratio lacks any theoretical basis as a proxy for cancer survival. It is not a valid proxy for cancer survival in practice, either, whether at 5 years or at any other time interval since diagnosis. It has none of the useful properties of a population-based survival estimate. It should not be used as a surrogate for cancer survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Age FactorsCause of DeathFemaleHistory, 20th CenturyHistory, 21st CenturyHumansIncidenceMaleMortalityNeoplasmsPublic Health SurveillanceRegistriesReproducibility of ResultsRisk Factors

Autor:innen und Institutionen

  • London School of Hygiene and Tropical Medicine, London, United Kingdom.

Förderung

  • Cancer Research UK

Zitieren

APA

Ellis, L., Belot, A., Rachet, B., & Coleman, M. P. (2019). The Mortality-to-Incidence Ratio Is Not a Valid Proxy for Cancer Survival. Journal of Global Oncology, 1-9. https://doi.org/10.1200/jgo.19.00038

Vancouver

Ellis L, Belot A, Rachet B, Coleman MP. The Mortality-to-Incidence Ratio Is Not a Valid Proxy for Cancer Survival. Journal of Global Oncology. 2019:1-9. doi:10.1200/jgo.19.00038

BibTeX
@article{Ellis2019,
  author = {Ellis, Libby and Belot, Aurélien and Rachet, Bernard and Coleman, Michel P},
  title = {The Mortality-to-Incidence Ratio Is Not a Valid Proxy for Cancer Survival},
  journal = {Journal of Global Oncology},
  year = {2019},
  number = {5},
  pages = {1--9},
  doi = {10.1200/jgo.19.00038}
}
Kostenlos starten →